Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (721-730 of 934) with videos related to

Pageof 94
Sort By:
Circulation|April 23, 2008
Impact of time of presentation on the care and outcomes of acute myocardial infarctionHani Jneid, Gregg C Fonarow, Christopher P Cannon, et al.
European Heart Journal|November 13, 2012
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosisDharam J Kumbhani, P Gabriel Steg, Christopher P Cannon, et al.
JAMA|October 4, 2012
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery diseaseSripal Bangalore, Gabriel Steg, Prakash Deedwania, et al.
Journal of the American Heart Association|April 18, 2020
Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance ProgramsJacob A Doll, Lisa A Kaltenbach, Kevin J Anstrom, et al.
European Heart Journal|April 19, 2018
Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trialsHarsh B Golwala, Christopher P Cannon, Ph Gabriel Steg, et al.
The American Journal of Cardiology|November 24, 1999
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B InvestigatorsC M Gibson, C P Cannon, S A Murphy, et al.
The American Journal of Cardiology|February 16, 2010
Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)Christopher P Cannon, Karen E Rhee, Robert M Califf, et al.
Circulation|June 29, 2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trialKenneth W Mahaffey, Daniel M Wojdyla, Kevin Carroll, et al.
Journal of the American College of Cardiology|May 7, 2011
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudyBenjamin M Scirica, Christopher P Cannon, Håkan Emanuelsson, et al.
International Journal of Cardiology|June 23, 2020
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS programClare Arnott, Brendon L Neuen, Hiddo J L Heerspink, et al.
Pageof 94

Showing results (721-730 of 934) with videos related to

Sort By:
Pageof 94
Circulation|April 23, 2008
Impact of time of presentation on the care and outcomes of acute myocardial infarctionHani Jneid, Gregg C Fonarow, Christopher P Cannon, et al.
European Heart Journal|November 13, 2012
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosisDharam J Kumbhani, P Gabriel Steg, Christopher P Cannon, et al.
JAMA|October 4, 2012
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery diseaseSripal Bangalore, Gabriel Steg, Prakash Deedwania, et al.
Journal of the American Heart Association|April 18, 2020
Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance ProgramsJacob A Doll, Lisa A Kaltenbach, Kevin J Anstrom, et al.
European Heart Journal|April 19, 2018
Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trialsHarsh B Golwala, Christopher P Cannon, Ph Gabriel Steg, et al.
The American Journal of Cardiology|November 24, 1999
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B InvestigatorsC M Gibson, C P Cannon, S A Murphy, et al.
The American Journal of Cardiology|February 16, 2010
Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)Christopher P Cannon, Karen E Rhee, Robert M Califf, et al.
Circulation|June 29, 2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trialKenneth W Mahaffey, Daniel M Wojdyla, Kevin Carroll, et al.
Journal of the American College of Cardiology|May 7, 2011
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudyBenjamin M Scirica, Christopher P Cannon, Håkan Emanuelsson, et al.
International Journal of Cardiology|June 23, 2020
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS programClare Arnott, Brendon L Neuen, Hiddo J L Heerspink, et al.
Pageof 94